Vein of Marshall ethanol infusion for recurrent atrial fibrillation in patients with durably isolated pulmonary veins.
Atrial fibrillation ablation
Ethanol ablation
Pulmonary vein isolation
Vein of Marshall
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
27
02
2024
accepted:
09
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Vein of Marshall (VoM) ethanol ablation has a proven benefit in patients with persistent atrial fibrillation (AF) undergoing index procedure; however, its role in repeat ablation is unknown. We sought to evaluate the benefit of empiric VoM ethanol ablation in addition to posterior wall isolation (PWI) during the repeat procedure in patients with durable pulmonary vein (PV) isolation from prior ablation. Twenty-three patients (age 67.1 + / - 7.4, 74% males) who received empiric VoM ethanol infusion in addition to PWI were matched for age, gender, ejection fraction, and left atrial size with forty-six patients receiving empiric PWI alone. All patients in the study group underwent additional ablation on mitral isthmus to complete the lateral mitral isthmus line. Additional ablation was based on program and trigger stimulation. Primary outcome was freedom from AF after a blanking period of 3 months by qualification of symptoms, EKG, wearable, or implantable monitor or device. The study group had a higher average BMI (35.07 + / - 8.98 vs. 30.85 + / - 5.65, p = 0.033) and rate of persistent AF (83.0% vs. 54.3%, p = 0.029) versus the control. The 1-year AF-free survival for the study and control groups was 20 (86.96%) and 28 (60.1%) patients (p = 0.027). Cox proportional hazard regression analysis showed a significant reduction in AF recurrence in the study group (HR 0.25, 95% CI 0.073-0.843, p = 0.026). Among patients undergoing repeat catheter ablation for recurrent AF with durably isolated PVs, the addition of VoM ethanol infusion increased the likelihood of remaining free from AF at 12 months.
Sections du résumé
BACKGROUND
BACKGROUND
Vein of Marshall (VoM) ethanol ablation has a proven benefit in patients with persistent atrial fibrillation (AF) undergoing index procedure; however, its role in repeat ablation is unknown. We sought to evaluate the benefit of empiric VoM ethanol ablation in addition to posterior wall isolation (PWI) during the repeat procedure in patients with durable pulmonary vein (PV) isolation from prior ablation.
METHODS
METHODS
Twenty-three patients (age 67.1 + / - 7.4, 74% males) who received empiric VoM ethanol infusion in addition to PWI were matched for age, gender, ejection fraction, and left atrial size with forty-six patients receiving empiric PWI alone. All patients in the study group underwent additional ablation on mitral isthmus to complete the lateral mitral isthmus line. Additional ablation was based on program and trigger stimulation. Primary outcome was freedom from AF after a blanking period of 3 months by qualification of symptoms, EKG, wearable, or implantable monitor or device.
RESULTS
RESULTS
The study group had a higher average BMI (35.07 + / - 8.98 vs. 30.85 + / - 5.65, p = 0.033) and rate of persistent AF (83.0% vs. 54.3%, p = 0.029) versus the control. The 1-year AF-free survival for the study and control groups was 20 (86.96%) and 28 (60.1%) patients (p = 0.027). Cox proportional hazard regression analysis showed a significant reduction in AF recurrence in the study group (HR 0.25, 95% CI 0.073-0.843, p = 0.026).
CONCLUSION
CONCLUSIONS
Among patients undergoing repeat catheter ablation for recurrent AF with durably isolated PVs, the addition of VoM ethanol infusion increased the likelihood of remaining free from AF at 12 months.
Identifiants
pubmed: 39078545
doi: 10.1007/s10840-024-01877-w
pii: 10.1007/s10840-024-01877-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Walfridsson H, Walfridsson U, Nielsen JC, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. MANTRA-PAF Trial Europace. 2015;17(2):215–21.
pubmed: 25567068
Morillo CA, Verma A, Connolly SJ, RAAFT-2 investigators, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692–700.
doi: 10.1001/jama.2014.467
pubmed: 24549549
Callans DJ, Gerstenfeld EP, Dixit S, et al. Efficacy of repeat pulmonary vein isolation procedures in patients with recurrent atrial fibrillation. J Cardiovasc Electrophysiol. 2004;15(9):1050–5.
doi: 10.1046/j.1540-8167.2004.04052.x
pubmed: 15363079
Gerstenfeld EP, Callans DJ, Dixit S, Zado E, Marchlinski FE. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. J Cardiovasc Electrophysiol. 2003;14(7):685–90.
doi: 10.1046/j.1540-8167.2003.03013.x
pubmed: 12930245
Nanthakumar K, Plumb VJ, Epstein AE, et al. Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation. 2004;109(10):1226–9.
doi: 10.1161/01.CIR.0000121423.78120.49
pubmed: 14993124
Darby AE. Recurrent atrial fibrillation after catheter ablation: considerations for repeat ablation and strategies to optimize success. J Atr Fibrillation. 2016;9(1):1427.
pubmed: 27909521
pmcid: 5089515
Verma A, Mantovan R, Macle L, et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J. 2010;31(11):1344–56.
doi: 10.1093/eurheartj/ehq041
pubmed: 20215126
pmcid: 2878965
Verma A, Jiang CY, Betts TR, STAR AF II Investigators, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812–22.
doi: 10.1056/NEJMoa1408288
pubmed: 25946280
Dixit S, Marchlinski FE, Lin D, et al. Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm Electrophysiol. 2012;5(2):287–94.
doi: 10.1161/CIRCEP.111.966226
pubmed: 22139886
Fink T, Schlüter M, Heeger CH, et al. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized Alster-Lost-AF trial (Ablation at St. George Hospital for Long-Standing Persistent Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017;10(7):e005114.
doi: 10.1161/CIRCEP.117.005114
pubmed: 28687670
Valderrábano M, Peterson LE, Swarup V, et al. Effect of catheter ablation with Vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial. JAMA. 2020;324(16):1620–8.
doi: 10.1001/jama.2020.16195
pubmed: 33107945
Dave AS, Báez-Escudero JL, Sasaridis C, et al. Role of the vein of Marshall in atrial fibrillation recurrences after catheter ablation: therapeutic effect of ethanol infusion. J Cardiovasc Electrophysiol. 2012;23(6):583–91.
doi: 10.1111/j.1540-8167.2011.02268.x
pubmed: 22429895
Leyton-Mange JS, Tandon K, Sze EY, Carpenter CM, Sesselberg HW. The Maine vein of Marshall ethanol experience: learning curve and safety. J Interv Card Electrophysiol. 2023;66(3):661–71. https://doi.org/10.1007/s10840-022-01378-8 .
doi: 10.1007/s10840-022-01378-8
pubmed: 36181632
Takigawa M, Takahashi A, Kuwahara T, et al. Impact of non-pulmonary vein foci on the outcome of the second session of catheter ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26(7):739–46.
doi: 10.1111/jce.12681
pubmed: 25845757
Ikenouchi T, Nitta J, Inaba O, Kono T, Murata K, Takamiya T, Inamura Y, Sato A, Matsumura Y, Takahashi Y, Goya M, Sasano T. Effect of isolation feasibility of non-pulmonary vein foci on efficacy of ablation for atrial fibrillation: comparison of the isolation and focal ablation methods. J Interv Card Electrophysiol. 2022;65(2):441–51. https://doi.org/10.1007/s10840-022-01217-w .
doi: 10.1007/s10840-022-01217-w
pubmed: 35445888
Elayi CS, Di Biase L, Bai R, Burkhardt JD, Mohanty P, Santangeli P, Sanchez J, Hongo R, Gallinghouse GJ, Horton R, Bailey S, Beheiry S, Natale A. Administration of isoproterenol and adenosine to guide supplemental ablation after pulmonary vein antrum isolation. J Cardiovasc Electrophysiol. 2013;24(11):1199–206. https://doi.org/10.1111/jce.12252 .
doi: 10.1111/jce.12252
pubmed: 24020649
Crawford T, Chugh A, Good E, Yoshida K, Jongnarangsin K, Ebinger M, Pelosi F Jr, Bogun F, Morady F, Oral H. Clinical value of noninducibility by high-dose isoproterenol versus rapid atrial pacing after catheter ablation of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21(1):13–20. https://doi.org/10.1111/j.1540-8167.2009.01571.x .
doi: 10.1111/j.1540-8167.2009.01571.x
pubmed: 19682170
Aldaas OM, Darden D, Mylavarapu PS, Han FT, Hoffmayer KS, Krummen D, Ho G, Raissi F, Feld GK, Hsu JC. Association of isoproterenol infusion during catheter ablation of atrial fibrillation with outcomes: insights from the UC San Diego AF Ablation Registry. J Interv Card Electrophysiol. 2023;66(5):1243–52. https://doi.org/10.1007/s10840-022-01448-x .
doi: 10.1007/s10840-022-01448-x
pubmed: 36508065